Keyphrases
Abatacept
19%
Adjunctive Therapy
11%
All-cause Mortality
9%
Amphotericin B
10%
Antifungal Therapy
10%
Asthma
9%
Attributable Mortality
9%
Azoles
16%
B Cells
11%
Candida Bloodstream Infection
19%
Cenicriviroc
11%
Clinical Prediction Model
19%
Confidence Interval
14%
COVID-19
100%
COVID-19 Pneumonia
12%
Cryptococcal Infection
19%
Cryptococcosis
21%
Disease Severity
10%
Disseminated Infection
14%
Fungal Infection
10%
Group Education
15%
Group Research
15%
Histoplasmosis
59%
Hospitalized Patients
13%
Immune Status
10%
Immunocompromised Patients
12%
Infliximab
19%
Intubated Patients
9%
Invasive Fungal Infection
31%
Itraconazole
30%
Master Protocol
11%
Modern History
20%
Mycoses
25%
Odds Ratio
14%
Patients with COVID-19
14%
People Living with HIV (PLHIV)
17%
Placebo
16%
Propensity Score Analysis
9%
Randomized Clinical Trial
13%
Research Consortium
15%
Retrospective Cohort
11%
Rezafungin
9%
Safety Profile
12%
SARS-CoV-2 Infection
20%
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
21%
Single Center
10%
Step-down
14%
T-2307
9%
Toxic Interaction
9%
United States
12%
Pharmacology, Toxicology and Pharmaceutical Science
Abatacept
19%
Addison Disease
9%
Adult Respiratory Distress Syndrome
9%
Adverse Outcome
9%
All Cause Mortality
9%
Amphotericin B
10%
Antifungal Agent
9%
Antifungal Therapy
9%
Antiinfective Agent
12%
Asthma
9%
Aureobasidin A
9%
Bioavailability
9%
Bloodstream Infection
19%
Candida
22%
Candidiasis
9%
Cenicriviroc
11%
Chloroquine
9%
Clostridium Difficile Infection
9%
Cohort Study
10%
Comorbidity
10%
Coronavirinae
29%
Cryptococcosis
19%
Diseases
58%
Drug Resistance
9%
Echinocandins
9%
Fluconazole
11%
Histoplasmosis
40%
HIV
9%
Hydroxychloroquine
9%
Ibrexafungerp
9%
Infection
47%
Infliximab
19%
Invasive Candidiasis
9%
Itraconazole
30%
Lactobacillus rhamnosus
9%
Mineralocorticoid
9%
Mitochondrial DNA
9%
Mycosis
29%
Nikkomycin Z
9%
Olorofim
9%
Paralysis
9%
Placebo
22%
Pyrrole Derivative
10%
Randomized Clinical Trial
13%
Randomized Controlled Trial
9%
Rezafungin
9%
Route of Administration
9%
SARS Coronavirus
31%
Systemic Mycosis
29%
Voriconazole
9%
Medicine and Dentistry
Abatacept
19%
Acute Respiratory Distress Syndrome
9%
Adjuvant Therapy
11%
Adverse Outcome
9%
Antifungal Therapy
10%
Antigen Antibody Reaction
9%
Asthma
9%
Aureobasidin A
9%
Blastomycosis
9%
Bloodstream Infection
9%
Cell Wall
9%
Cenicriviroc
11%
Chloroquine
9%
Clostridium Difficile Infection
9%
Coccidioidomycosis
9%
Cohort Analysis
9%
Complement Activation
9%
Coronavirinae
9%
COVID-19
86%
Cryptococcosis
21%
Dimorphic Fungal Infection
9%
Disease Severity
10%
Diseases
31%
Disseminated Disease
13%
Drug Resistance
9%
Echinocandins
9%
Enzyme Linked Immunosorbent Assay
9%
Geographic Distribution
9%
Histoplasmosis
28%
Human Immunodeficiency Virus
17%
Hydroxychloroquine
9%
Ibrexafungerp
9%
Infection
64%
Infliximab
19%
Lateral Flow Assay
9%
Meta-Analysis
9%
Microbiome
9%
Mineralocorticoid
9%
Mitochondrial DNA
9%
Mycosis
19%
Nikkomycin Z
9%
Olorofim
9%
Paralysis
9%
Placebo
19%
Pyrrole Derivative
9%
Randomized Clinical Trial
13%
Rezafungin
9%
Secondary Data
9%
Severe Acute Respiratory Syndrome Coronavirus 2
52%
Systemic Mycosis
20%
